Who are Placebe of HS-25 and Atorvastatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Crestor, Lipitor, FLUVASTATIN SODIUM, Lescol, atorvastatin plus ezetimibe, pravastatin, rosuvastatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebe-of-hs-25-and-atorvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Placebe of HS-25 and Atorvastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebe of HS-25 and Atorvastatin (Placebe of HS-25 and Atorvastatin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: statin. Area: Cardiovascular.

phase 3 statin HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Placebe of HS-25 and Atorvastatin (Placebe of HS-25 and Atorvastatin) — Zhejiang Hisun Pharmaceutical Co. Ltd.. Atorvastatin is a statin that inhibits HMG-CoA reductase to lower cholesterol levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebe of HS-25 and Atorvastatin TARGET	Placebe of HS-25 and Atorvastatin	Zhejiang Hisun Pharmaceutical Co. Ltd.	phase 3	statin	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
atorvastatin plus ezetimibe	atorvastatin plus ezetimibe	Shanghai Jiao Tong University School of Medicine	marketed	Statin plus cholesterol absorption inhibitor combination	HMG-CoA reductase; NPC1L1 transporter
pravastatin, rosuvastatin	pravastatin, rosuvastatin	Yokohama City University Medical Center	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2037-06-07 — Lipitor · 11654106 · US
2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (statin class)

FutureChem · 1 drug in this class
HTA Co., Ltd. · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
VA Office of Research and Development · 1 drug in this class
Zhejiang Hisun Pharmaceutical Co. Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebe of HS-25 and Atorvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebe-of-hs-25-and-atorvastatin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab